JPH1084879A - Fraction of crude soybean lecithin having function to suppress synthesis of neutral fat in liver - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a fraction which is safe as foods or drinks, animal feeds and medicines without side effects and has effects to suppress synthesis of neutral fat in a liver and to prevent or cure a fat liver by fractionating a crude soybean lecithin produced in the production process of an oil from soybeans. SOLUTION: A crude soybean lecithin produced in the production process of an oil from soybeans is fractionated to obtain a crude soybean fraction. This fraction is phosphatidyl choline or phosphatidyl ethanolamine and has an effect to suppress synthesis of neutral fat in a liver. The fraction is insoluble in methanol and acetone but soluble in chloroform-methanol.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a crude soybean lecithin fraction having an activity of inhibiting hepatic triglyceride synthesis.

[0002]

2. Description of the Related Art In recent years, liver diseases caused by eating habits have become a major problem. In particular, fatty liver caused by excessive drinking of alcohol, overnutrition, and malnutrition is known to cause cirrhosis. In the treatment of fatty liver, it is important to eliminate the cause, and abstinence and diet are the basis. However, since it is difficult to change eating habits such as abstinence and diet, an effective and simple method for preventing and treating fatty liver is required.

As a technique for solving these problems, drug therapy for fatty liver has been developed, and multivitamin preparations, polyenephosphatidylcholine, pantethine and the like are used. However, multivitamin supplements are vitamin supplements,
Polyene phosphatidylcholine is used to improve hyperlipidemia, and pantethine is used to improve lipid metabolism of hepatocytes, and is only an adjuvant treatment for fatty liver. In addition, these drugs are generally expensive and are difficult to use on a daily basis from the viewpoint of preventing fatty liver.

[0004] In normal fatty liver, most of the accumulated lipids are triglycerides. Therefore, if the synthesis of triglycerides in the liver can be suppressed, this is an effective means for preventing and treating fatty liver. . Drugs that have an inhibitory effect on hepatic triglyceride synthesis include nicotinic acid preparations for hyperlipidemia and fibrates, all of which have hepatic dysfunction as a side effect and are suitable for the treatment of fatty liver. Absent. On the other hand, as a food ingredient, vegetable protein such as soy protein has been reported to inhibit hepatic triglyceride synthesis, but it requires a large amount of intake and is not a practical hepatic triglyceride synthesis inhibitor.

[0005] In view of these points, an object of the present invention is to suppress hepatic triglyceride synthesis, which is inexpensive, can be used on a daily basis, and can be used safely for the prevention and treatment of fatty liver without side effects. It is to realize a composition having an action.

[0006]

In order to solve the above-mentioned problems, the present inventors have conducted intensive studies on the relationship between various plant components and the effect of suppressing hepatic triglyceride synthesis. It has been found that the present invention has an extremely strong hepatic triglyceride synthesis inhibitory effect, and the present invention has been completed. That is,
The present invention is a crude soybean lecithin fraction having a hepatic triglyceride synthesis inhibitory effect obtained by fractionating crude lecithin produced in the step of producing fats and oils from soybeans.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION As a crude soybean lecithin fraction,
The crude lecithin generated in the process of producing soybean oil may be fractionated with an organic solvent, an adsorbent, an ion exchange resin, or the like,
In particular, an insoluble fraction obtained by treating crude soybean lecithin with methanol, acetone or the like is preferable, and a soluble fraction obtained by treating with chloroform-methanol is preferable.
In addition, a soluble fraction of crude soybean lecithin with hot methanol can also be used. Further, as the fraction of the present invention, phosphatidylcholine or phosphatidylethanolamine purified from the fraction may be used alone.

When phosphatidylcholine or phosphatidylethanolamine is used as the fraction of the present invention, it is obtained by separating and purifying crude lecithin obtained from soybean by ion exchange column chromatography, silica gel column chromatography, thin layer chromatography, or the like. be able to. Further, phosphatidylethanolamine may be synthesized from phosphatidylcholine by a base exchange reaction using an enzyme. Phosphatidylcholine is sometimes referred to as lecithin and phosphatidylethanolamine is referred to as kephalin as a common name. Lecithin, as used herein, is a mixture of several types of phospholipids and is used separately from phosphatidylcholine.

[0009] Lecithin has been widely used as an emulsifier for foods and has no problem in safety. Also, lecithin is known to have various physiological functions, such as lowering blood cholesterol and liver cholesterol that cause arteriosclerosis, and crude lecithin is fractionated by fractionating crude soybean lecithin. It would be extremely significant if it could be used as a crude soybean lecithin fraction with improved flavor and handling properties and enhanced liver neutral fat synthesis inhibitory action.

[0010]

Examples are shown below. Example of production of crude soybean lecithin In the production process of soybean oil, 2% by weight of warm water is added to the crude oil obtained by extracting hexane from the raw soybean oil and stirred, and the resulting lecithin hydrate is recovered by centrifugation. did. The obtained gum-like lecithin hydrate was dehydrated to obtain crude soybean lecithin (about 60% by weight of acetone-insoluble portion). Each fraction was obtained using the obtained crude soybean lecithin in the following Reference Examples.

Reference Example 1 A 10-fold volume of methanol was added to crude soybean lecithin, and the mixture was sufficiently stirred, and a methanol-insoluble portion was recovered. After methanol was distilled off with a rotary evaporator, 10 volumes of cold acetone was added, sufficiently crushed and dispersed in a mortar, and allowed to stand. The supernatant was discarded, 10 volumes of cold acetone were added again, and the same operation was repeated twice. The obtained acetone-insoluble part was dissolved in chloroform, methanol and distilled water were added thereto, and the mixture was stirred, and the lower layer was recovered by a separating funnel. The residual solvent is distilled off with a rotary evaporator and dried under reduced pressure to obtain chloroform-
A methanol-soluble portion (hereinafter, referred to as AY3) was obtained.

Reference Example 2 On the other hand, in order to examine the action of a phospholipid alone, a phospholipid was purified. Five times the volume of hot methanol (60 ° C.) was added to the crude soybean lecithin, and the mixture was sufficiently stirred. After cooling to 10 ° C., the mixture was allowed to stand to remove insolubles. The methanol extract thus obtained was passed through an acetic acid type basic ion exchange resin, and a phospholipid fraction eluted first was collected. The residual solvent was distilled off using a rotary evaporator, and the residue was dried under reduced pressure to obtain phosphatidylcholine (PC) having a purity of 97.4%.

Reference Example 3 Further, the phosphatidylcholine obtained in Reference Example 2 was dissolved in diethyl ether, mixed with a citrate buffer containing a high concentration of ethanolamine hydrochloride, and treated with phospholipase D
And vigorously stirred at room temperature. After the completion of the reaction, the mixture was allowed to stand for a while, and then the diethyl ether layer was recovered and washed three times with distilled water. The residual ether is distilled off by a rotary evaporator and dried under reduced pressure to obtain 96.5% pure phosphatidylethanolamine (PE).
I got

Test Example 1 A 6-week-old male KK mouse was allowed to freely ingest water and the synthetic feed described in Table 1. After breeding all groups on a high-calorie diet for 2 weeks, the group was divided into three groups (6 or 7 animals per group), and a low-calorie diet was used as a control group. The groups to which the PE described in No. 3 was added in an amount of 0.04% by weight were provided as test groups, respectively, and reared for further 2 weeks. Separately, mice were bred similarly, and a test was conducted using a low-calorie diet supplemented with 0.04% by weight of AY3 described in Reference Example 1. Table 1 shows the feed composition of the high calorie diet and the low calorie diet.

[0015]

[Table 1] Note) Mineral mix and vitamin mix are manufactured by Oriental Yeast Co., Ltd.

After completion of the breeding test, the mice were dissected and the weight of the liver tissue of each group of mice was measured, and neutral fat and total cholesterol were analyzed by conventional methods. Table 2 shows the results of the PC and PE administration groups, and Table 3 shows the results of the AY3 administration group. The triglyceride and total cholesterol concentrations in the PC group showed lower values than those in the control group, although there was no significant difference. The neutral fat and total cholesterol concentrations in the PE group were significantly lower than those in the control group (Table 2). The neutral fat in the AY3 group showed a significantly lower value than the control group (Table 3). From these results, it was clarified that the crude soybean lecithin fraction of the present invention reduced hepatic triglyceride by blending at extremely low doses. In addition, the crude soybean lecithin fraction of the present invention is mixed with a low-fat diet, and the use of dietary fat in the liver of mice is slight. It was shown that neutral fat synthesis was suppressed in From the results of the AY3 group, AY3
It can be inferred that a similar result can be obtained in an insoluble fraction obtained by treating crude soybean lecithin before obtaining with methanol or acetone.

[0017]

[Table 2] Note) Each value is shown as the mean ± standard deviation. 1) There is a significant difference from the control group at a risk rate of 5% or less. 2) There is a significant difference from the control group when the risk factor is 1% or less.

[0018]

[Table 3] Note) Each value is shown as the mean ± standard deviation. 1) There is a significant difference from the control group at a risk rate of 5% or less.

Test Example 2 The effect of the crude soybean lecithin fraction of the present invention on neutral fat synthesis in the liver was examined in a fasting-refeeding system in which the synthesis of neutral fat in the liver was enhanced. Using an 8-week-old male KK mouse, all groups were fasted for 2 days and then divided into 3 groups (6 or 7 animals per group), and a high carbohydrate diet was set as a control group. The test group was re-fed for 3 days with the PC described in No. 2 or the one to which 0.4% by weight of PE described in Reference Example 3 was added. Table 4 shows the feed composition of the high carbohydrate diet.

[0020]

[Table 4] 1) Mineral mix and vitamin mix are manufactured by Oriental Yeast Co., Ltd.

After completion of the breeding test, the mice were dissected and the weight of liver tissue of each group of mice was measured, and neutral fat and total cholesterol were analyzed by a conventional method. Table 5 shows the results. In the control group, the synthesis of triglyceride in the liver was enhanced and the triglyceride concentration was increased, whereas the triglyceride concentration in the PC group was suppressed from increasing, which was significantly higher than that in the control group. It showed a low value. Furthermore, in the PE group, the increase in neutral fat and total cholesterol levels was significantly suppressed, and showed a significantly lower value than the control group (Table 5). These results indicate that the crude soybean lecithin fraction of the present invention has a neutral fat synthesis inhibitory action in the liver.

[0022]

[Table 5] Note) Each value is shown as the mean ± standard deviation. 1) There is a significant difference from the control group at a risk rate of 5% or less. 2) There is a significant difference from the control group when the risk factor is 1% or less.

[0023]

As described above, the crude soybean lecithin fraction of the present invention has an effect of inhibiting the synthesis of neutral fat in the liver, and has various effects conventionally used for the treatment of fatty liver. It is cheaper than drugs, and is expected to have the effect of preventing and treating liver diseases such as fatty liver by taking it as food. The crude soybean lecithin fraction can be blended with known raw materials to form a food, drink, animal feed or pharmaceutical preparation, and can be used safely without side effects.

 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Kotaro Muroyama 2-69, Maison de Orc 303, Founder Itami-shi, Hyogo (72) Inventor Sanae Sumitani 3-9-20 Sumiyoshi Yamate, Higashinada-ku, Kobe-shi, Hyogo (72) Inventor Hiroshi Harada 1-7-40 Oiwake, Shimizu-shi, Shizuoka Prefecture (72) Inventor Yutaka Otani 1055 Matsubara, Asaba-cho, Iwata-gun, Shizuoka Prefecture Cotton Field A202 (72) Inventor Kazuya Ikuta Oiwake, Shimizu-shi Shizuoka Prefecture 1-7-40

Claims (6)

[Claims] 1. A crude soybean lecithin fraction having a hepatic triglyceride synthesis inhibitory effect obtained by fractionating crude soybean lecithin generated in the step of producing fats and oils from soybeans. 2. The crude soybean lecithin fraction according to claim 1, wherein the nature of the fraction is insoluble in methanol. 3. The crude soybean lecithin fraction according to claim 1, wherein the fraction is insoluble in acetone. 4. The crude soybean lecithin fraction according to claim 1, wherein the fraction is soluble in chloroform-methanol. 5. The crude soybean lecithin fraction according to claim 1, wherein the fraction is phosphatidylcholine. 6. The crude soybean lecithin fraction according to claim 1, wherein the fraction is phosphatidylethanolamine.